retatrutide trial phase Shows 28% Weight Loss in 80 Weeks When does the first phase
Description
Not too shabby, right

doi: 10.1124/jpet.111.181529

Tang-Christensen M., Larsen P
Tirzepatide is administered as a once-weekly subcutaneous injection, with doses gradually titrated from 2.5 mg up to a maximum of 15 mg over several months

In addition, regulatory bodies are becoming more supportive of new therapies, which may further accelerate the approval process for GLP 1 analogues

Los efectos sobre control glucmico y FRCV asociados a SEMA 2,4mg en el programa STEP son cualitativamente similares, pero cuantitativamente superiores a los observados con LIRA 3mg, en posible relacin con la diferente prdida ponderal16